FI95347C - Menetelmä nifedipiinipitoisen farmaseuttisen seoksen valmistamiseksi - Google Patents
Menetelmä nifedipiinipitoisen farmaseuttisen seoksen valmistamiseksi Download PDFInfo
- Publication number
- FI95347C FI95347C FI900633A FI900633A FI95347C FI 95347 C FI95347 C FI 95347C FI 900633 A FI900633 A FI 900633A FI 900633 A FI900633 A FI 900633A FI 95347 C FI95347 C FI 95347C
- Authority
- FI
- Finland
- Prior art keywords
- nifedipine
- particles
- polyvinylpyrrolidone
- process according
- pharmaceutically acceptable
- Prior art date
Links
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 229960001597 nifedipine Drugs 0.000 title claims abstract description 54
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000002245 particle Substances 0.000 claims abstract description 37
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 26
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 26
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 26
- 239000003085 diluting agent Substances 0.000 claims abstract description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000007892 solid unit dosage form Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 8
- 239000007909 solid dosage form Substances 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 238000010348 incorporation Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898903328A GB8903328D0 (en) | 1989-02-14 | 1989-02-14 | Nifedipine-containing pharmaceutical compositions and process for the preparation thereof |
| GB8903328 | 1989-02-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI900633A0 FI900633A0 (fi) | 1990-02-08 |
| FI95347B FI95347B (fi) | 1995-10-13 |
| FI95347C true FI95347C (fi) | 1996-01-25 |
Family
ID=10651674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI900633A FI95347C (fi) | 1989-02-14 | 1990-02-08 | Menetelmä nifedipiinipitoisen farmaseuttisen seoksen valmistamiseksi |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5145683A (OSRAM) |
| EP (1) | EP0385582B1 (OSRAM) |
| JP (1) | JPH07112974B2 (OSRAM) |
| AT (1) | ATE79032T1 (OSRAM) |
| AU (1) | AU626130B2 (OSRAM) |
| CA (1) | CA2008972C (OSRAM) |
| DE (1) | DE69000240T2 (OSRAM) |
| DK (1) | DK0385582T3 (OSRAM) |
| ES (1) | ES2052168T3 (OSRAM) |
| FI (1) | FI95347C (OSRAM) |
| GB (1) | GB8903328D0 (OSRAM) |
| GR (1) | GR3005477T3 (OSRAM) |
| IE (1) | IE64682B1 (OSRAM) |
| NO (1) | NO175925C (OSRAM) |
| NZ (1) | NZ232287A (OSRAM) |
| PH (1) | PH26850A (OSRAM) |
| ZA (1) | ZA90904B (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5624683A (en) * | 1986-08-06 | 1997-04-29 | Eisai Co., Ltd. | Sustained-release multi-granule tablet |
| GB9200607D0 (en) * | 1992-01-13 | 1992-03-11 | Ethical Pharma Ltd | Pharmaceutical compositions containing nifedipine and process for the preparation thereof |
| US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
| US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US6726930B1 (en) | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| ES2168351T3 (es) * | 1994-12-29 | 2002-06-16 | Shire Deutschland Gmbh & Co Kg | Preparaciones farmaceuticas que contienen nifedipina y procedimiento para su preparacion. |
| US5871776A (en) * | 1995-01-31 | 1999-02-16 | Mehta; Atul M. | Controlled-release nifedipine |
| CN1049114C (zh) * | 1995-12-07 | 2000-02-09 | 上海华联制药公司 | 一种制备缓释药物制剂的方法 |
| CA2231195C (en) * | 1996-07-08 | 2003-01-21 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
| EP0852141A1 (en) | 1996-08-16 | 1998-07-08 | J.B. Chemicals & Pharmaceuticals Ltd. | Nifedipine containing pharmaceutical extended release composition and a process for the preparation thereof |
| IT1284604B1 (it) * | 1996-09-27 | 1998-05-21 | Roberto Valducci | Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva |
| US5837379A (en) * | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
| US5922352A (en) * | 1997-01-31 | 1999-07-13 | Andrx Pharmaceuticals, Inc. | Once daily calcium channel blocker tablet having a delayed release core |
| IN186245B (OSRAM) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| US6485748B1 (en) | 1997-12-12 | 2002-11-26 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
| US6168806B1 (en) | 1999-03-05 | 2001-01-02 | Fang-Yu Lee | Orally administrable nifedipine pellet and process for the preparation thereof |
| US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
| JP4627825B2 (ja) * | 1999-09-27 | 2011-02-09 | 三生医薬株式会社 | 被包粒状物質及びその製造方法 |
| MXPA01005370A (es) * | 1999-09-30 | 2004-05-14 | Penwest Pharmaceuticals Co | Sistema de matriz de liberacion sostenida para farmacos altamente solubles. |
| RU2188635C2 (ru) * | 1999-10-12 | 2002-09-10 | Открытое акционерное общество "Щелковский витаминный завод" | Композиционный состав лекарственного средства - блокатора медленных кальциевых каналов |
| CA2359945C (en) * | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| US20030130297A1 (en) * | 2001-07-06 | 2003-07-10 | Endo Pharmaceuticals, Inc. | Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US20080181948A1 (en) * | 2006-11-15 | 2008-07-31 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
| GB2462022B (en) * | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
| RU2629843C1 (ru) * | 2016-05-24 | 2017-09-04 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) | Способ получения мази нифедипина (варианты) |
| CN109172534B (zh) * | 2018-10-23 | 2020-08-07 | 迪沙药业集团有限公司 | 一种硝苯地平缓释片剂组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
| US4285665A (en) * | 1978-05-08 | 1981-08-25 | Johnson, Matthey & Co., Limited | Engines |
| DE3033919A1 (de) * | 1980-09-09 | 1982-04-22 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung |
| JPS5846019A (ja) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | 持続性ニフエジピン製剤 |
| DE3318649A1 (de) * | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | Zweiphasenformulierung |
| FR2556964A1 (fr) * | 1983-12-23 | 1985-06-28 | Ile De France | Nouvelles formes galeniques du sulpiride utilisables par voie orale |
| DE3424553A1 (de) * | 1984-07-04 | 1986-01-09 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung |
| IT1178511B (it) * | 1984-09-14 | 1987-09-09 | Pharmatec Spa | Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio |
| IT1187751B (it) * | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
| SE457326B (sv) * | 1986-02-14 | 1988-12-19 | Lejus Medical Ab | Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa |
-
1989
- 1989-02-14 GB GB898903328A patent/GB8903328D0/en active Pending
-
1990
- 1990-01-25 IE IE28690A patent/IE64682B1/en not_active IP Right Cessation
- 1990-01-26 NO NO900370A patent/NO175925C/no unknown
- 1990-01-30 US US07/472,659 patent/US5145683A/en not_active Expired - Lifetime
- 1990-01-30 NZ NZ232287A patent/NZ232287A/en unknown
- 1990-01-31 EP EP90301005A patent/EP0385582B1/en not_active Expired - Lifetime
- 1990-01-31 DK DK90301005.6T patent/DK0385582T3/da active
- 1990-01-31 CA CA002008972A patent/CA2008972C/en not_active Expired - Fee Related
- 1990-01-31 ES ES90301005T patent/ES2052168T3/es not_active Expired - Lifetime
- 1990-01-31 AU AU48937/90A patent/AU626130B2/en not_active Ceased
- 1990-01-31 DE DE9090301005T patent/DE69000240T2/de not_active Expired - Fee Related
- 1990-01-31 AT AT90301005T patent/ATE79032T1/de not_active IP Right Cessation
- 1990-02-07 ZA ZA90904A patent/ZA90904B/xx unknown
- 1990-02-08 FI FI900633A patent/FI95347C/fi not_active IP Right Cessation
- 1990-02-09 PH PH40039A patent/PH26850A/en unknown
- 1990-02-13 JP JP2032325A patent/JPH07112974B2/ja not_active Expired - Lifetime
-
1992
- 1992-08-20 GR GR920401816T patent/GR3005477T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE64682B1 (en) | 1995-08-23 |
| IE900286L (en) | 1990-08-14 |
| GB8903328D0 (en) | 1989-04-05 |
| FI95347B (fi) | 1995-10-13 |
| DK0385582T3 (da) | 1992-09-14 |
| NO175925C (no) | 1995-01-04 |
| US5145683A (en) | 1992-09-08 |
| DE69000240D1 (de) | 1992-09-10 |
| DE69000240T2 (de) | 1993-02-11 |
| AU4893790A (en) | 1990-08-23 |
| NO900370D0 (no) | 1990-01-26 |
| NZ232287A (en) | 1992-01-29 |
| EP0385582A1 (en) | 1990-09-05 |
| JPH07112974B2 (ja) | 1995-12-06 |
| ES2052168T3 (es) | 1994-07-01 |
| PH26850A (en) | 1992-11-05 |
| CA2008972C (en) | 1996-09-03 |
| EP0385582B1 (en) | 1992-08-05 |
| CA2008972A1 (en) | 1990-08-14 |
| ZA90904B (en) | 1991-06-26 |
| JPH02235815A (ja) | 1990-09-18 |
| AU626130B2 (en) | 1992-07-23 |
| FI900633A0 (fi) | 1990-02-08 |
| ATE79032T1 (de) | 1992-08-15 |
| NO175925B (no) | 1994-09-26 |
| NO900370L (no) | 1990-08-15 |
| GR3005477T3 (OSRAM) | 1993-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI95347C (fi) | Menetelmä nifedipiinipitoisen farmaseuttisen seoksen valmistamiseksi | |
| DE69627835T2 (de) | Feste pharmazeutische zusammensetzung aus nanopartikeln | |
| AT402889B (de) | Nifedipinpräparate mit einer regulierten wirkstoffabgabe und verfahren zur herstellung derselben | |
| CA1264441A (en) | Galenical retard form | |
| JPH01500998A (ja) | 被覆膜及びそれから調製された組成物 | |
| CH648484A5 (de) | Pharmazeutische zubereitung eines festen medikamentmaterials. | |
| JPS5914446B2 (ja) | ニフエジピン含有固形製剤及びその製造方法 | |
| WO2004100944A1 (en) | Bicalutamide forms, compositions, and processes thereof | |
| JP2013535454A (ja) | ドロネダロン固形分散剤およびその製造法 | |
| Yamashita et al. | Expedited tablet formulation development of a highly soluble carbamazepine cocrystal enabled by precipitation inhibition in diffusion layer | |
| PL168605B1 (pl) | Sposób wytwarzania doustnych form dawek o kontrolowanym wydzielaniu substancji czynnej PL | |
| CA2637925A1 (en) | Levetiracetam formulations and methods for their manufacture | |
| HU208495B (en) | Process for producing retarde pharmaceutical compositions | |
| DE10153934A1 (de) | Verfahren zur Kristallisation von Profenen | |
| EA007153B1 (ru) | Твердая дисперсная композиция | |
| JPS62228017A (ja) | ジヒドロピリジンを含有する固体の迅速放出性薬剤調製物の製造方法 | |
| EA015440B1 (ru) | Твердая лекарственная форма, содержащая полиморфную форму 1 клопидогрела гидросульфата | |
| KR19980701292A (ko) | 수지 입자, 의약 재료 및 수지 입자를 함유하는 약제학적제제(Resin particle, medical material and pharmaceutical preparation containing said resin particle) | |
| WO2007007182A2 (en) | Solid and liquid dosage forms of an antiepileptic agent | |
| KR940008415B1 (ko) | 코팅 막과 그로부터 제조된 조성물 | |
| CA3094550A1 (en) | Instant release pharmaceutical preparation of anticoagulant and preparation method therefor | |
| CH670201A5 (en) | Solid dispersions of water-insol. drugs - comprising coherent crystals of drug in water-soluble matrix | |
| KR890001501B1 (ko) | 조절된 서방성을 지닌 활성제의 고형분산액 제조방벙 | |
| JPS6110507A (ja) | 新規遅効性製剤 | |
| TR2021002085A2 (tr) | Api̇ksaban'in fi̇lm kapli bi̇r tableti̇ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| MM | Patent lapsed |
Owner name: ETHICAL PHARMACEUTICALS LTD |